Pricing Log in Create free account

Aclaris Therapeutics, Inc. (ACRS) vs Valneva SE Sponsored ADR (VALN)

Aclaris Therapeutics, Inc. and Valneva SE Sponsored ADR are both Biotechnology companies. Aclaris Therapeutics, Inc. and Valneva SE Sponsored ADR are of similar size ($559.5M and $536.5M). Aclaris Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Valneva SE Sponsored ADR trades at 59.3×. Valneva SE Sponsored ADR grew revenue faster over the last twelve months: −53.2% against −59.3%. Valneva SE Sponsored ADR has the higher net margin (−12.0% vs −1,244.1%) and the higher return on invested capital (0.00% vs −107.7%). Across the 18 metrics below, Valneva SE Sponsored ADR leads on 14 and Aclaris Therapeutics, Inc. on 4.

Valuation

Metric ACRS VALN Biotechnology median
P/E n/m 59.26 10.60
P/S 90.59 3.02 9.40
P/B 3.48 5.26 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 42.64 0.66
EV/Sales 74.41 3.47 9.02
Earnings yield (14.95%) 1.69% (32.88%)
Free cash flow yield (12.99%) (11.87%) (23.13%)

Profitability

Metric ACRS VALN Biotechnology median
Gross margin 0.00% 38.28% 68.51%
Operating margin (1,413.97%) 13.56% 0.00%
Net margin (1,244.09%) (12.01%) 0.00%
Free cash flow margin (1,176.61%) 0.00% 0.00%
Return on equity (55.51%) 0.00% (51.96%)
Return on assets (40.66%) 0.00% (46.06%)
Return on invested capital (107.72%) 0.00% 0.00%

Growth

Metric ACRS VALN Biotechnology median
Revenue growth (TTM) (59.34%) (53.16%) 6.76%
EPS growth (last fiscal year) 69.01% (805.88%) 29.88%
Revenue growth, 5-year CAGR 3.84% 9.41% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACRS VALN Biotechnology median
Debt to equity 0.00 2.27 0.00
Current ratio 5.09 2.16 4.97
Net debt to EBITDA 1.20 (1.15) 1.01

Dividend

Metric ACRS VALN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ACRS VALN Biotechnology median
Market cap 559.49m 536.53m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack